---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122298"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:24:20.543946+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M

## Summary
- Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.
- Gross margin 75.4%, +670 bps; backlog record 316 units (+71%); 225 MyoPro orders (+44%).
- Raised FY2024 revenue guidance to $30-31M from prior $28-30M; expects Q4 rev $9.5-10.5M.
- Cash $7.0M; expects approaching operating cash flow breakeven in Q4.
- Cost per pipeline add $1,618, down 25%; 1,263 patients in pipeline (+21%).

## SEC filing metadata
- accession: 0000950170-24-122298
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017024122298/0000950170-24-122298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017024122298/myo-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122298
- JSON: https://secwatch.observer/filing/0000950170-24-122298.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.